Bluebird bio — Company Overview, News & Financial Data
Bluebird bio develops gene therapies for genetic diseases, focusing on innovative solutions for severe medical conditions.
Bluebird bio
Company profile
About Bluebird bio
Bluebird bio (NASDAQ:BLUE) is a biotechnology company focused on developing gene therapies for severe genetic diseases and cancer. The company is known for its pioneering work in gene editing and cell therapy, aiming to create treatments that can offer profound and durable benefits to patients. Its pipeline includes projects targeting conditions like sickle cell disease, beta-thalassemia, and multiple myeloma. With a commitment to addressing some of the most challenging medical conditions, Bluebird bio seeks to transform the landscape of genetic medicine through its innovative approaches and dedication to patients' well-being.
Snapshot
1992Year founded
323Employees
Somerville, United StatesHead office
Loading Map...
Global footprint
Operations
All Locations
Somerville, US
Products and/or services of Bluebird bio
- Zynteglo, a gene therapy for beta-thalassemia, a blood disorder that reduces the production of hemoglobin.
- LentiGlobin, a gene therapy under development for sickle cell disease, aiming to reduce or eliminate episodes of pain.
- skysona, a gene therapy for cerebral adrenoleukodystrophy, a rare genetic disorder affecting the brain and adrenal glands.
- BB305 Lentiviral Vector, a gene therapy product targeting various hematologic and genetic disorders by inserting functional genes into patients' cells.
- Lenti-D, an experimental gene therapy for treating adrenoleukodystrophy, specifically focusing on stopping the progression of cerebral adrenoleukodystrophy.
- Gene therapy platform, utilizing lentiviral vectors for the development of treatments for genetic diseases, including cancer.
Bluebird bio executive team
- Mr. Andrew ObenshainPresident, CEO & Director
- Mr. Thomas J. KlimaChief Commercial & Operating Officer
- Mr. Joseph D. Vittiglio Esq., J.D.Chief Legal & Business Officer and Secretary
- Mr. Oliver James Sterling IIICFO & Principal Accounting Officer
- Ms. Andrea WaltonChief People Officer
- Dr. Richard A. Colvin M.D., Ph.D.Chief Medical Officer
- Mr. Scott ShoemakerSenior Vice President of Technical Operations
GET YOUR GRAFA EDGE NOW
Sign up free to follow this company
We'll switch on a 30-day Edge trial as a welcome gift